US guided treat-to-target approach in early RA: Implications for uncoupling of disease activity and structural joint damage

Current Rheumatology Reviews

Volumn 11, Issue 1, 2015, Pages 18-27

  El Miedany, Yasser ^a,b   El Gaafary, Maha ^c   Ahmed, Ihab ^d   Youssef, Sally ^a   Nasr, Annie ^c  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b DARENT VALLEY HOSPITAL   (United Kingdom)

^c AIN SHAMS UNIVERSITY   (Egypt)

^d CAIRO UNIVERSITY   (Egypt)

Author keywords

Early arthritis; Joint damage; PROMs; Rheumatoid arthritis; Uncoupling; US

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE;

ADULT; ARTHROPATHY; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; DISEASE ACTIVITY; DRUG DOSE INCREASE; ECHOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCORING SYSTEM; STRUCTURAL JOINT DAMAGE; X RAY;

EID: 84934756335     PISSN: 15733971     EISSN: 18756360     Source Type: Journal    
DOI: 10.2174/1573397111666150522095749     Document Type: Article

References (49)

1. Lillegraven S, van der Heijde D, Uhlig T, et al. What is the clinical relevance of erosions and joint space narrowing in RA? Nat Rev Rheumatol 2012; 8: 117-20.
2. Keystone E. Recent concepts in the inhibition of radiographic progression with biologics. Curr Opin Rheum 2009; 21: 231-7.
3. El Miedany Y, El Gaafary M, Palmer D, Youssef S. Imaging As An Outcome Measure in Early Inflammatory Arthritis: Monitoring Disease Activity and Patients' Response to Therapy Using Ultrasonography. Arthritis Rheumatism 2011; 63(10): S319.
4. Van Leeuwen MA, van Rijswijk MH, Sluiter WJ, et al. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol 1997; 24: 20-7.
5. Boers M, van Tuyl L, van den Broek M et al. Meta-analysis suggests that intensive non-biological combination therapy with stepdown prednisolone (COBRA strategy) may also 'disconnect' disease activity and damage in rheumatoid arthritis. Ann Rheum Dis 2013; 72: 406-409.
6. Landewe R, van der Heijde D, Klareskog L, et al. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate. Arthritis Rheum 2006; 54: 3119-25.
7. Smolen JS, van der Heijde DM, Keystone EC, et al. Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. Ann Rheum Dis 2012.
8. Smolen JS, Han C, Bala M, et al. for the ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005; 52: 1020-30.
9. Emery P, Genovese MC, van Vollenhoven R, et al. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol 2009; 36: 1429-41.
10. Smolen JS, Avila JCM, Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its antiinflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis 2012; 71: 687-93.
11. Aletaha D, Alasti F, Smolen JS. Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients. Ann Rheum Dis 2013; 72(1): 7-12.
12. Smolen JS, Aletaha D, Bijlsma JW, et al. for the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
13. Villeneuve E, Haraoui B. Uncoupling of disease activity and structural damage. Does it matter clinically? Ann Rheum Dis 2013; 72 (1): 1-2.
14. Emery P, Fleischmann R, van der Heijde D, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 2011; 63: 1200-10.
15. Aletaha D, Neogi T, Silman A et al. 2010 Rheumatoid Arthritis Classification Criteria. Arthritis Rheum 2010; 62 (9): 2569-2581.
16. El Miedany Y, El Gaafary M, Youssef S, Palmer D. Incorporating Patient Reported Outcome Measures in Clinical Practice: Development and Validation of a questionnaire for Inflammatory arthritis. Clin Exp Rheumatol 2010; 28: 734-744.
17. National Institute for Health and Clinical Excellence (2009) The Management of Rheumatoid Arthritis in Adults. NICE, London. www. nice. org. uk/CG79 (Accessed 16 June 2011).
18. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000; 27: 261-3.
19. Ory P. Interpreting radiographic data in rheumatoid arthritis. Ann Rheum Dis 2003; 62: 597-604.
20. Backhaus M, Burmester GR, Gerber T, et al. Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis 2001; 60: 641-9.
21. Wakefield RJ, Balint PV, Szkudlarek M, et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 2005; 32: 2485-7.
22. Karim Z, Wakefield RJ, Quinn M, et al. Validation and reproducibility of ultrasonography in the detection of synovitis in the knee: a comparison with arthroscopy and clinical examination. Arthritis Rheum 2004; 50: 387-94.
23. Wakefield RJ, Green MJ, Marzo-Ortega H, et al. Shouldoligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. Ann Rheum Dis 2004; 63: 382-5.
24. El Miedany Y, El Gaafary M, Youssef S et al. Tailored approach to early psoriatic arthritis patients: clinical and ultrasonographic predictors for structural joint damage. Clin Rheumatol (2015) 34: 307-313.
25. van Leeuwen MA, van der Heijde DM, van Rijswijk MH, et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 1994; 21: 425-9.
26. Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796-806.
27. Smolen JS, Van Der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006; 54: 702-10.
28. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
29. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
30. Landewe R, van der Heijde D, Klareskog L, et al. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate. Arthritis Rheum 2006; 54: 3119-25.
31. Smolen JS, van der Heijde DM, Keystone EC, et al. Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. Ann Rheum Dis 2013; 72(7): 1156-62.
32. Smolen JS, Han C, Bala M, et al. for the ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005; 52: 1020-30.
33. Villeneuve E, Haraoui B. Uncoupling of disease activity and structural damage. Does it matter clinically? Ann Rheum Dis 2013; 72: 1-2.
34. El Miedany Y, El Gaafary M, Youssef S, Nasr A. Arthritis Rheum 2013; 65(10): S1331.
35. Smolen JS, Avila JC, Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its antiinflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis 2012; 71: 687-93.
36. GarneroP, Landewe R, Bores M et al. Association of baseline levels of markers of bone and cartilage degradation with longterm progression of joint damage in patients with early rheumatoid arthritis. The COBRA study. Arthritis Rheum 2002; 46: 2847-56.
37. LandeweR, GeusensP, Bores M et al.: Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum 2004; 50: 1390-9.
38. Udagawa N, Takahashi N, Katagiri T, Tamura T, Wada S, Findlay DM, Martin TJ, Hirota H, Tada T, Kishimoto T, Suda T 1995 Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med 182: 1461-1468.
39. Mukai T, Otsuka F, Otani H, Yamashita M, Takasugi K, Inagaki K, Yamamura M, Makino H. TNF-alpha inhibits BMP-induced osteoblast differentiation through activating SAPK/JNK signaling. BiochemBiophys Res Commun 2007; 356(4): 1004-10.
40. Mukai T, Otsuka F, Otani H et al. TNF-alpha inhibits BMPinduced osteoblast differentiation through activating SAPK/JNK signaling. BiochemBiophys Res Commun 2007; 356(4): 1004-10.
41. Stanley C, Dore R, Lane N et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008; 58 (5): 1299-1309.
42. Manolagas S. Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis. Endocrine Reviews 2000; 21(2): 115-137.
43. Lipsky PE, Felson DT, Maini R. Blocking tumor necrosis factor inhibits radiographic damage even in patients who show minimal or no clinical improvement: comment on the concise communication by Boers [letter]. Arthritis Rheum 2002; 46: 2817.
44. Boers M, for the COBRA Study. Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Arthritis Rheum 2001; 44: 2703-4.
45. Macchioni P, Magnani M, Mulè R et al. Ultrasonographic predictors for the development of joint damage in rheumatoid arthritis patients: a single joint prospective study. Clin Exp Rheumatol 2012; 1-10.
46. Witt M, Mueller F, Nigg A et al. Relevance of Grade 1 Gray-Scale Ultrasound Findings in Wrists and Small Joints to the Assessment of Subclinical Synovitis in Rheumatoid Arthritis. Arthritis Rheum 2013; 65 (7): 1694-1701.
47. Karsdal M, Madsen S, Christiansen C et al. Cartilage degradation is fully reversible in the presence of aggrecanas but not matrix metalloproteinase activity. Arthritis Research & Therapy 2008; 10: R63.
48. Kirwan J, Byron M, Watt I. The relationship between soft tissue swelling, joint space narrowing and erosive damage in hand x-rays of patients with rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 297-301.
49. Strand V, Sharp JT. Radiographic data from recent randomized controlled trials in rheumatoid arthritis: what have we learned? Arthritis Rheum 2003; 48: 21-34.